Orforglipron and Levothyroxine: Is It Safe to Take Together?

There’s no specific interaction between orforglipron (Foundayo) and levothyroxine flagged in the FDA-approved FOUNDAYO label, and plenty of people take both — one for weight management, the other for thyroid hormone replacement. The real nuance isn’t a drug-drug interaction so much as a timing question, because levothyroxine is unusually sensitive to how and when it’s taken, and orforglipron’s own effect on digestion is worth understanding before you assume your existing routine doesn’t need a second look.

What each drug does

Orforglipron (brand Foundayo, Eli Lilly) is a once-daily oral GLP-1 receptor agonist, FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. Per its label, it’s taken once daily with or without food, with no water restriction.

Levothyroxine (brand names include Synthroid) is a synthetic thyroid hormone used to treat hypothyroidism (an underactive thyroid) by replacing the hormone the thyroid isn’t producing enough of on its own. It isn’t a GLP-1 medication and doesn’t share orforglipron’s mechanism — but it’s well known in pharmacy practice for being sensitive to absorption conditions: what’s in the stomach, timing relative to food, and interactions with certain supplements and minerals can all affect how much of the dose actually gets absorbed.

Because the two drugs work through entirely different pathways, taking them together isn’t unusual. The question people actually have is narrower: does orforglipron’s effect on digestion change how levothyroxine gets absorbed.

Is there a labeled interaction?

Per the FOUNDAYO label on DailyMed, orforglipron’s interaction warnings center on two things: its effect on gastric emptying (which can potentially affect absorption of other oral medications taken around the same time) and an increased hypoglycemia risk when combined with insulin or insulin secretagogues such as sulfonylureas. Levothyroxine isn’t called out specifically in either context.

That absence is informative but not a guarantee of zero effect. A label not naming a specific combination means the manufacturer hasn’t identified or studied a clinically significant interaction worth flagging — it doesn’t mean every possible absorption nuance has been ruled out. For a medication like levothyroxine, where dosing precision matters, that’s a reasonable thing to raise with your prescriber or pharmacist rather than assume away.

Why gastric emptying matters here specifically

GLP-1 receptor agonists work partly by slowing how quickly the stomach empties into the small intestine, where most oral drugs — including levothyroxine — are absorbed. That mechanism is central to how orforglipron affects appetite and blood sugar, and it’s also the reason the FOUNDAYO label notes a general potential to affect other oral medications’ absorption. For our fuller rundown of how this mechanism intersects with other drug classes, see Orforglipron Drug Interactions.

Orforglipron doesn’t carry Rybelsus’s (oral semaglutide’s) strict empty-stomach, limited-water, 30-minutes-before-anything-else rule — per its label, it’s taken with or without food, no water restriction, which is one of its main practical differences from Rybelsus. But “no timing rule for orforglipron’s own absorption” isn’t the same as “no possible effect on how something else, like levothyroxine, is absorbed.”

Levothyroxine’s own timing sensitivity

Independent of orforglipron, levothyroxine dosing routines are typically built around consistency — taking it the same way, relative to food and other substances, day after day — because that consistency is what keeps blood levels stable and labs predictable. Adding a new medication that affects gastric emptying is exactly the kind of change worth flagging to whoever manages your levothyroxine, so they can decide whether your existing routine needs any adjustment or just closer lab monitoring for a while.

	Orforglipron (Foundayo)	Levothyroxine
Food/water rule per its own label	None — with or without food, no water restriction	Absorption is timing- and food-sensitive; routines are typically kept consistent
Mechanism relevant here	Slows gastric emptying, which can affect absorption of other oral drugs	Is itself an oral drug whose absorption can be affected by what’s taken alongside it
Labeled interaction between the two	Not specifically flagged	Not specifically flagged
What to do	Take as prescribed	Keep your existing routine unless your prescriber changes it, and mention orforglipron at your next visit

This table isn’t a personalized dosing instruction — it’s a summary of what each label does and doesn’t say, to help frame the conversation with your prescriber or pharmacist.

This is a different topic from orforglipron’s thyroid boxed warning

It’s easy to conflate two separate “orforglipron and thyroid” topics, so it’s worth being explicit: orforglipron carries an FDA boxed warning about thyroid C-cell tumors, a class-wide GLP-1 precaution linked to rodent studies and to reports of medullary thyroid carcinoma (MTC) in people taking other GLP-1 receptor agonists. That warning is about a rare cancer risk and who shouldn’t take the drug at all (people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2). It has nothing to do with whether orforglipron interacts with levothyroxine, a hormone-replacement drug for an underactive thyroid. Our does orforglipron cause thyroid cancer guide covers that boxed warning in full; this article is only about the absorption-timing question.

What to bring to your prescriber or pharmacist

If you’re taking or starting both medications, come prepared with:

• Your levothyroxine dose, how long you’ve been stable on it, and what time of day you take it
• Your orforglipron dose and how far along you are in titration (see How to Take Orforglipron for the schedule)
• Whether you’ve had recent thyroid labs, and when your next check is due
• Any GI symptoms — nausea, vomiting, diarrhea — since those can also affect how consistently you’re able to take either medication

That level of detail lets your prescriber or pharmacist reason about your actual regimen instead of a generic interaction summary.

What this article won’t do

This isn’t a substitute for a pharmacist- or prescriber-reviewed medication check, and it doesn’t establish a specific interaction that isn’t in the FDA label — there’s no published data here to invent a risk figure from. If you take levothyroxine and are starting or already on orforglipron, that combination is a conversation for your prescriber, who can weigh your thyroid labs and full health history.

Bottom line

Orforglipron and levothyroxine work through unrelated mechanisms, and the FOUNDAYO label doesn’t flag a specific interaction between them. The practical consideration is that orforglipron can slow gastric emptying, which has the general potential to affect absorption of other oral medications, and levothyroxine is a drug where absorption consistency already matters. Keep your levothyroxine routine as prescribed, mention orforglipron to whoever manages your thyroid treatment, and don’t confuse this timing question with orforglipron’s separate boxed warning about thyroid cancer risk.

For the broader picture on starting orforglipron, see Foundayo (Orforglipron): A Simple Guide.